№ lp_2_2_04131
File format: docx
Character count: 8288
File size: 46 KB
Ethyl acetate handling and safety procedures in laboratory environments including storage, protective equipment, and waste disposal guidelines.
Note:
Year
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Authors:
Erika Parkinson; Maja Aleksic; Rachael Arthur; Sergio Regufe Da Mota; Richard Cubberley; Paul J. Skipp
Corresponding author:
Paul Skipp, Ph.D.
Affiliations:
Biological Sciences, University of Southampton; Centre for Proteomic Research, Institute for Life Sciences, University of Southampton; Safety & Environmental Assurance Centre, Unilever, Colworth Science Park
Region:
Southampton, UK; Sharnbrook, UK
Thematic area:
Proteomics; Skin sensitisation; Allergic contact dermatitis; Chemical toxicology
Keywords:
allergic contact dermatitis; Diphencyprone; Ethyl Acrylate; HSA; MSE; proteomics; sensitization; skin
Abbreviations:
Diphenylcyclopropenone (DPCP); Diphencyprone; Ethyl Acrylate (EA); Human Serum Albumin (HSA); HaCaT
Type of document:
Scientific research article
Subject of study:
Protein haptenation in HSA and HaCaT cell lysates induced by DPCP and EA
Methodology:
Stable isotope labelling combined with data-independent acquisition mass spectrometry (HDMSE/DIA)
Institutional context:
Academic and industry collaboration
Contact information:
Tel +44 (0)2380 594204; Fax +44 (0)2380 594459; Email [email protected]
Year:
2024
Region / City:
Australia
Subject:
Endometriosis treatment
Document Type:
Medical submission
Organization:
Gedeon Richter Australia Pty Ltd
Author:
Gedeon Richter Australia Pty Ltd
Target Audience:
Medical professionals, health authorities
Period of validity:
Ongoing
Approval Date:
31 January 2024
Modification Date:
Not specified
Note:
Version Number 2.3
Year:
2025
Region / City:
United Kingdom
Theme:
Sexual and Reproductive Health
Document Type:
Patient Group Direction (PGD)
Organisation:
Faculty of Sexual and Reproductive Health (FSRH)
Author:
Dr. Cindy Farmer, Michelle Jenkins, Elaine Scott, Kalpesh Thakrar, Sim Sesane, Tanya Lane, Kate Devonport, Chetna Parmar, Carmel Lloyd, Clare Livingstone, Portia Jackson, Kirsty Armstrong, Dipti Patel, Emma Anderson, Alison Crompton, Lisa Knight, Bola Sotubo, Tracy Rogers, Sandra Wolper, Jo Jenkins, Rosie Furner
Target Audience:
Registered healthcare professionals authorised to practice under this PGD
Period of Effect:
May 2023 - April 2026
Approval Date:
December 2022
Review Date:
October 2025
Expiry Date:
April 2026
Year:
2022
Region / City:
Australia
Topic:
Medicinal Product Submission
Document Type:
Submission for Pharmaceutical Listing
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Not specified
Target Audience:
Healthcare professionals, policy makers
Period of Validity:
Not specified
Approval Date:
10 August 2022
Date of Changes:
Not specified
Year:
2015
Region / city:
Australia
Topic:
Pharmacoeconomic Evaluation, Pharmaceutical Policy
Document Type:
Submission
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC), Shire Australia Pty Ltd
Author:
Shire Australia Pty Ltd
Target Audience:
Healthcare professionals, policymakers
Period of Effectiveness:
2015-2020
Approval Date:
July 2015
Revision Date:
None indicated
Year:
2026
Region / City:
United Kingdom
Theme:
Pharmaceutical Treatment
Document Type:
Prescribing Information
Organization:
NHS
Author:
Dr. Joanne Ritchie
Target Audience:
Healthcare professionals, specifically specialists and GPs
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Contraindications:
Venous thromboembolic disorder, arterial thromboembolic disease, known thrombophilic disorders, known osteoporosis, headaches with focal neurological symptoms, pregnancy, breastfeeding
Monitoring:
DEXA scan recommended after 1 year of treatment
Special Warnings/Precautions:
Use of non-hormonal contraception for at least 1 month after initiation
Adverse Effects:
Hot flushes, headache
Primary Care responsibilities for continuation:
Prescribe as recommended, seek advice from the specialist if needed
Specialist Service responsibilities for initiation:
Discuss benefits and side effects with the patient, initiate treatment and monitor
Criteria for Discontinuation:
Menopause, increase in migraine frequency, ATE/VTE events, acute liver deterioration
Date of Initiation:
Not specified
Communication:
Contact details for the specialist and hospital pharmacy provided
Year:
2023
Region / city:
UK
Topic:
Healthcare, Pharmaceuticals, Antifungal Treatment
Document Type:
Prescribing Information
Organization:
NAPP Pharmaceuticals Ltd
Author:
NAPP Pharmaceuticals Ltd
Target Audience:
UK Healthcare Professionals
Period of validity:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
United Kingdom
Subject:
Reproductive health; contraceptive administration
Document type:
Patient Group Direction (PGD)
Authorising body:
College of Sexual and Reproductive Healthcare (CoSRH)
PGD development group:
Reproductive Health PGDs Short Life Working Group (SLWG)
Approving organisations:
NHS Trusts and local health authorities
Target audience:
Registered healthcare professionals authorised to use the PGD
Effective date:
1 May 2026
Review date:
1 November 2028
Expiry date:
30 April 2029
Version:
3.0
Change history:
Includes updates on contraindications, cautions, and terminology alignment with UKMEC 2025 and CoSRH guidance
Training requirements:
Authorised HCPs must complete specified education and competency assessment
Legal compliance:
Must be signed by senior doctor, senior pharmacist, and organisational representative
Description:
Official national PGD detailing the conditions, contraindications, administration procedure, and authorisation requirements for SC-DMPA use by qualified healthcare professionals, including a comprehensive version history and governance framework.
Year:
2021
Region / City:
Not specified
Topic:
Clinical study, oncology, prostate cancer
Document Type:
Study Protocol
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, clinical researchers
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2009
Region / City:
Cairo, Giza
Topic:
Hormone residues in fish
Document Type:
Research Study
Organization / Institution:
Faculty of Veterinary Medicine, Benha University; Animal Health Research Institute, Dokki, Giza
Author:
Hemmat M; Reham A; Omaima M D; Asmaa E H
Target Audience:
Researchers, Aquaculture Specialists
Action Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / City:
N/A
Topic:
Registration Service, Operational Choreography
Document Type:
Change Request
Organization:
MHHS Programme
Author:
N/A
Target Audience:
Programme Participants
Period of Validity:
N/A
Approval Date:
08/02/2023
Date of Changes:
N/A
Organization:
United Nations Development Programme
Country:
Kuwait
Document type:
Standard Operating Procedures
Subject area:
Project cycle management
Implementation modality:
National Implementation Modality with Country Office support
Strategic framework:
UNDP Strategic Plan 2014–2017
Programme framework:
Country Programme Document and Country Programme Action Plan 2015–2018
Responsible institution:
UNDP Kuwait Country Office
Government coordinating agency:
General Secretariat of the Supreme Council for Planning and Development
Scope:
UNDP programmes and projects implemented in Kuwait
Project phases covered:
Formulation, appraisal, implementation, monitoring, evaluation, extension and closure
Intended users:
UNDP staff and national implementing partners
Annexes included:
Capacity assessment checklist, project document template, risk logs template, quality assurance checklist
Year:
Contract Year No.
Supplier:
Legal Name of Supplier
Facility:
Name of Facility
Contract:
Contract Title / Contract ID
Contract Date:
Contract Date
Time Period:
From insert date To insert date
Contract Capacity (MW):
Contract Capacity
Planned Outages:
As specified per unit and month
Unplanned Outages:
Percentage per unit and month
Overall Availability:
Percentage per unit and month
Type of Document:
Prescribed Form – Annual Operating Plan
Audience:
Buyer and Contract Management
Source:
Independent submission under Section 14.3(b)(i) of the Contract
Note:
Year
Issuing authority:
Ministry for Primary Industries
Jurisdiction:
New Zealand
Legal basis:
Biosecurity Act 1993
Document type:
Operating manual
Facility type:
Transitional Facility for uncleared risk goods
Approval status:
Approved Transitional Facility
Regulatory standards referenced:
TFGEN (Standard for General Transitional Facilities for Uncleared Risk Goods)
Scope of activities:
Receipt, holding, processing, treatment and inspection of uncleared risk goods; inspection of imported containers
Responsible roles:
Transitional Facility Operator; Deputy Transitional Facility Operator; Accredited Person
Compliance requirements:
MPI inspection and verification audits; access for MPI Inspectors at any reasonable time
Version control:
Review and amendments record with dates and sections
Training requirements:
MPI-approved training and refresher training for operators and accredited persons
Operational areas covered:
Security, biosecurity equipment, inspections, record keeping, hygiene management, pest control, audits, contingency plans
Organization:
AMJ Construction
Topic:
Covid-19 health and safety measures
Document type:
Company policy
Industry:
Construction
Applicable guidelines:
Construction Leadership Council; Public Health England
Target audience:
Employees, site visitors, clients, supply chain partners
Date referenced:
11 May 2020
Scope:
Construction sites operated by AMJ Construction
Review frequency:
Weekly
Key measures:
Site inductions, risk assessments, cleaning regimes, social distancing, PPE, signage, adjusted working hours
Year:
2015
Region / City:
United Kingdom
Topic:
Tender Process, Procurement
Document Type:
Invitation to Tender
Authority:
Department of Health
Target Audience:
Potential Tenderers
Validity Period:
From 16/11/2015 to 27/11/2015
Approval Date:
16/11/2015
Amendment Date:
Not specified
Year:
2023
Region / City:
South Africa
Theme:
Food Business Operations, Agriculture
Document Type:
Standard Operating Procedure
Organization:
Department of Agriculture, Forestry and Fisheries (DAFF)
Author:
Not specified
Target Audience:
Food business operators, DAFF personnel, relevant stakeholders
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2025
Region / City:
Bloemfontein
Subject:
Procurement
Document Type:
Request for Bid (RFB)
Organization / Institution:
SITA
Author:
N/A
Target Audience:
Potential Bidders
Validity Period:
200 Days from the Closing Date
Approval Date:
N/A
Amendment Date:
N/A
Year:
2021
Region / City:
Air Force and Space Force Bases Worldwide
Subject:
CGOC Setup and Management
Document Type:
Guide
Organ / Institution:
Air Force National Company Grade Officers Council
Author:
Unknown
Target Audience:
Company grade officers, CGOC leaders
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Note:
Contextual Description